Caiji Lin

No. 157, Baojian Road
Harbin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Enterolactone and THBS1-3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment.

Enterolactone and THBS1-3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment.

Journal: British journal of pharmacology

Published: January 27, 2025

Multi-level inhibition of SARS-CoV-2 invasion by cannabidiol and epigallocatechin gallate.

Multi-level inhibition of SARS-CoV-2 invasion by cannabidiol and epigallocatechin gallate.

Journal: Virology

Published: December 14, 2024

Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis.

Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis.

Journal: British journal of pharmacology

Published: November 15, 2024

Mechanisms and benefits of phytochemicals as an alternative therapeutic strategy in female cancers.

Mechanisms and benefits of phytochemicals as an alternative therapeutic strategy in female cancers.

Journal: Chinese herbal medicines

Published: August 08, 2024

Enterolactone combined with m6A Reader IGF2BP3 inhibits malignant angiogenesis and disease progression in ovarian cancer.

Enterolactone combined with m6A Reader IGF2BP3 inhibits malignant angiogenesis and disease progression in ovarian cancer.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: May 30, 2024

Cannabidiol Inhibits Epithelial Ovarian Cancer: Role of Gut Microbiome.

Cannabidiol Inhibits Epithelial Ovarian Cancer: Role of Gut Microbiome.

Journal: Journal of natural products

Published: April 11, 2024

Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer.

Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer.

Journal: Journal of Cancer

Published: May 08, 2023

Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.

Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.

Journal: Phytotherapy research : PTR

Published: April 15, 2023

Trabectedin in Cancers: Mechanisms and Clinical Applications.

Trabectedin in Cancers: Mechanisms and Clinical Applications.

Journal: Current pharmaceutical design

Published: December 28, 2021

Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota.

Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: November 26, 2021

KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.

KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.

Journal: BMC cancer

Published: May 12, 2021

Suppressive activities of mangiferin on human epithelial ovarian cancer.

Suppressive activities of mangiferin on human epithelial ovarian cancer.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: January 17, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026